

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
PROSTATE.USPT.	9259
PROSTATES.USPT.	358
VACCIN\$	0
VACCIN.USPT.	50
VACCINA.USPT.	200
VACCINAA.USPT.	1
VACCINAE.USPT.	2
VACCINAFION.USPT.	1
VACCINAL.USPT.	1
VACCINAIAE.USPT.	1
VACCINAL.USPT.	357
(PROSTATE SAME VACCIN\$).USPT.	145

[There are more results than shown above. Click here to view the entire set.](#)

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L8

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**

DATE: Saturday, June 29, 2002 [Printable Copy](#) [Create Case](#)

Set	Items	Description
S1	18	(PSMA OR PROSTATE(W)SPECIFIC(W)MEMBRANE OR PSM) (20N) (TAA - OR TUMOR(W)ASSOCIATED OR TUMOUR(W)ASSOCIATED)
S2	10	RD S1 (unique items)
S3	42	(PSMA OR PROSTATE(W)SPECIFIC(W)MEMBRANE OR PSM) AND (TAA OR TUMOR(W)ASSOCIATED OR TUMOUR(W)ASSOCIATED)
S4	26	RD S3 (unique items)

S1 7 (CO(W)17(W)1A) AND NORMAL
? rd s1
...completed examining records
S2 3 RD S1 (unique items)
? t s2/7/all

2/7/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12984209 BIOSIS NO.: 200100191358
Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients.
AUTHOR: Staib Ludger; Birebent Brigitte; Somasundaram Rajasekharan; Purev Enkhtsetseg; Braumueller Heidi; Leeser Christian; Kuettner Norbert; Li Weiping; Zhu Dawei; Diao Jun; Wunner William; Speicher David; Beger Hans-Guenther; Song Hong; Herlyn Dorothee(a)
AUTHOR ADDRESS: (a)Wistar Institute, 3601 Spruce Street, Philadelphia, PA, 19104: Dherlyn@wistar.upenn.edu**USA
JOURNAL: International Journal of Cancer 92 (1):p79-87 1 April, 2001
MEDIUM: print
ISSN: 0020-7136
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: Targeting the GA733 antigen (also known as CO17-1A, EGP, KS1-4, KSA, Ep-CAM) by monoclonal antibody CO17-1A or anti-idiotypic antibodies mimicking the CO17-1A or GA733 epitope has induced prolonged survival and specific immune responses to the antigen, respectively, in colorectal cancer (CRC) patients. In pre-clinical studies in mice and rabbits, recombinant baculovirus-derived GA733-2E antigen was superior to anti-idiotypic antibodies at modulating specific immune responses. Our aim was to evaluate the immunogenicity and potential toxicity of alum-precipitated GA733-2E in a phase I trial in patients with resected CRC or pancreatic cancer. Six patients with advanced pancreatic carcinoma and 6 with CRC Dukes' stage A, B or C received between 4 and 7 doses of alum-precipitated GA733-2E at 50, 200 or 800 mug/dose at monthly intervals. Antibody binding to GA733-2E or antigen-positive CRC cells was determined, as were antigen-specific proliferative, cytolytic T-lymphocyte and delayed-type hypersensitivity responses. Six of the 12 patients developed antigen-specific humoral immune responses after immunotherapy, and 8 developed cellular immune responses. The overall immune response rate, including patients with humoral and/or cellular immune responses, was 83%. Median overall survival of the CRC and pancreatic cancer patients was 39.8 and 11.2 months, respectively. Following 18 years of single-epitope targeting of the GA733 antigen, immunization of patients against multiple epitopes of the antigen frequently induces an immune response in the absence of significant toxicity, despite relatively widespread expression of this antigen on normal epithelial cells.

2/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

09134442 BIOSIS NO.: 199497142812
Indium-111-labeled anti-EGFr-425 scintigraphy in the detection of malignant gliomas.
AUTHOR: Dadparvar Simin(a); Krishna Lalitha; Miyamoto Curtis; Brady Luther W; Brown Steven J; Bender Hans; Slizofski Walter J; Eshleman Jeffrey; Chevres Anita; Woo David V